185 related articles for article (PubMed ID: 12641451)
1. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of human cathepsin S.
McGrath ME; Palmer JT; Brömme D; Somoza JR
Protein Sci; 1998 Jun; 7(6):1294-302. PubMed ID: 9655332
[TBL] [Abstract][Full Text] [Related]
3. Peptide ketobenzoxazole inhibitors bound to cathepsin K.
McGrath ME; Sprengeler PA; Hill CM; Martichonok V; Cheung H; Somoza JR; Palmer JT; Janc JW
Biochemistry; 2003 Dec; 42(51):15018-28. PubMed ID: 14690410
[TBL] [Abstract][Full Text] [Related]
4. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine.
Sivaraman J; Nägler DK; Zhang R; Ménard R; Cygler M
J Mol Biol; 2000 Jan; 295(4):939-51. PubMed ID: 10656802
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors.
Shenoy RT; Sivaraman J
J Struct Biol; 2011 Jan; 173(1):14-9. PubMed ID: 20850545
[TBL] [Abstract][Full Text] [Related]
8. Carboxy-monopeptidase substrate specificity of human cathepsin X.
Devanathan G; Turnbull JL; Ziomek E; Purisima EO; Ménard R; Sulea T
Biochem Biophys Res Commun; 2005 Apr; 329(2):445-52. PubMed ID: 15737607
[TBL] [Abstract][Full Text] [Related]
9. Exploring inhibitor binding at the S' subsites of cathepsin L.
Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
[TBL] [Abstract][Full Text] [Related]
10. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain.
Rückrich T; Brandenburg J; Cansier A; Müller M; Stevanović S; Schilling K; Wiederanders B; Beck A; Melms A; Reich M; Driessen C; Kalbacher H
Biol Chem; 2006; 387(10-11):1503-11. PubMed ID: 17081125
[TBL] [Abstract][Full Text] [Related]
11. Species differences between human and rat in the substrate specificity of cathepsin K.
Tada S; Tsutsumi K; Ishihara H; Suzuki K; Gohda K; Teno N
J Biochem; 2008 Oct; 144(4):499-506. PubMed ID: 18664521
[TBL] [Abstract][Full Text] [Related]
12. Exploring the binding preferences/specificity in the active site of human cathepsin E.
Rao-Naik C; Guruprasad K; Batley B; Rapundalo S; Hill J; Blundell T; Kay J; Dunn BM
Proteins; 1995 Jun; 22(2):168-81. PubMed ID: 7567964
[TBL] [Abstract][Full Text] [Related]
13. The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex.
Li Z; Kienetz M; Cherney MM; James MN; Brömme D
J Mol Biol; 2008 Oct; 383(1):78-91. PubMed ID: 18692071
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
16. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
17. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex.
Tsuge H; Nishimura T; Tada Y; Asao T; Turk D; Turk V; Katunuma N
Biochem Biophys Res Commun; 1999 Dec; 266(2):411-6. PubMed ID: 10600517
[TBL] [Abstract][Full Text] [Related]
18. Defining the substrate specificity of mouse cathepsin P.
Puzer L; Barros NM; Oliveira V; Juliano MA; Lu G; Hassanein M; Juliano L; Mason RW; Carmona AK
Arch Biochem Biophys; 2005 Mar; 435(1):190-6. PubMed ID: 15680921
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
[TBL] [Abstract][Full Text] [Related]
20. A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors.
Shenoy RT; Chowdhury SF; Kumar S; Joseph L; Purisima EO; Sivaraman J
J Med Chem; 2009 Oct; 52(20):6335-46. PubMed ID: 19761244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
